检索
AI 对话
analysis
趋势分析
编组
开放平台
more
更多
排名必读论文期刊顶会热点AI 简史溯源树小脉星探人才迁徙塔尖人才国防情报追踪开源工具智慧手语
VIPCreated with Sketch.

A two-part, phase II, multi-center study of the ERK inhibitor ulixertinib (BVD-523) for patients with advanced malignancies harboring MEK or atypical BRAF alterations (BVD-523-ABC)

Mark E. Burkard,Meredith McKean,Jordi Rodon Ahnert,Niharika B. Mettu,Jeremy Clifton Jones,Jamal Ghazi Misleh,Wen Wee Ma,Kian-Huat Lim,E. Gabriela Chiorean,Michael J. Pishvaian,Shirish M. Gadgeel, Heidi Ann McKean, Brent Kreider,Deb Knoerzer, Anna Groover,Mary Laura Varterasian, Jessica A. Box,Caroline Emery,Ryan J. Sullivan

JOURNAL OF CLINICAL ONCOLOGY（2022）

引用 0|浏览15
暂无评分
关键词
erk inhibitor ulixertinib,advanced malignancies,atypical braf alterations,two-part,multi-center
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要